·      Spearhead ADME (Absorption, Distribution, Metabolism, Excretion) studies to support early-stage drug discovery projects.

·      Develop and optimise in-vitro assays, including metabolic stability, enzyme phenotyping, and drug-drug interaction studies.

·      Conduct high-throughput screening using liver microsomes, S9 fractions, and recombinant CYPs for compound profiling.

·      Analyse pharmacokinetic parameters (NCA) and provide actionable insights for candidate selection.

·      Develop and optimise LC-MS/MS methods for the quantification of small molecules and metabolites.

·      Maintain rigorous documentation and compliance with GLP standards.

·      Conducted rodent and non-rodent pharmacokinetic studies, supporting in vitro-to-in vivo translation (IVIVC) for early candidate selection.

·      Validated and developed time-dependent inhibition (TDI) assays (IC₅ shift method), glucuronidation and sulfation studies using S9 fractions and microsomes, contributing to expanded laboratory capabilities.

·      Spearhead ADME (Absorption, Distribution, Metabolism, Excretion) studies to support early-stage drug discovery projects.

·      Develop and optimise in-vitro assays, including metabolic stability, enzyme phenotyping, and drug-drug interaction studies.

·      Conduct high-throughput screening using liver microsomes, S9 fractions, and recombinant CYPs for compound profiling.

·      Analyse pharmacokinetic parameters (NCA) and provide actionable insights for candidate selection.

·      Develop and optimise LC-MS/MS methods for the quantification of small molecules and metabolites.

·      Maintain rigorous documentation and compliance with GLP standards.

·      Conducted rodent and non-rodent pharmacokinetic studies, supporting in vitro-to-in vivo translation (IVIVC) for early candidate selection.

·      Validated and developed time-dependent inhibition (TDI) assays (IC₅ shift method), glucuronidation and sulfation studies using S9 fractions and microsomes, contributing to expanded laboratory capabilities.